Compare NREF & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NREF | PROK |
|---|---|---|
| Founded | 2019 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 296.5M | 316.0M |
| IPO Year | N/A | 2021 |
| Metric | NREF | PROK |
|---|---|---|
| Price | $17.75 | $2.04 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $14.00 | $7.40 |
| AVG Volume (30 Days) | 38.1K | ★ 1.2M |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | ★ 13.95% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $893,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.47 | N/A |
| P/E Ratio | $4.78 | ★ N/A |
| Revenue Growth | N/A | ★ 1075.00 |
| 52 Week Low | $12.36 | $1.30 |
| 52 Week High | $18.43 | $3.48 |
| Indicator | NREF | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 60.22 | 71.06 |
| Support Level | $16.39 | $1.56 |
| Resistance Level | $18.27 | $2.22 |
| Average True Range (ATR) | 0.47 | 0.12 |
| MACD | 0.02 | 0.05 |
| Stochastic Oscillator | 71.67 | 92.25 |
NexPoint Real Estate Finance Inc is a commercial mortgage REIT focused on generating attractive, risk-adjusted returns for shareholders over the long term. The company invests mainly in first-lien mortgage loans, mezzanine loans, preferred equity, multifamily properties, and common equity investments, as well as multifamily and single-family rental CMBS securitizations, promissory notes, revolving credit facilities, and stock warrants. It focuses on real estate sectors where its management has operating expertise, including multifamily, single-family rental, self-storage, industrial, and life sciences, mainly in top metropolitan areas.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.